DUX4 Gene Silencing via CRISPR-Cas9 D4Z4 Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for facioscapulohumeral muscular dystrophy (FSHD) are inadequate, as they primarily target DUX4 mRNA or protein without effectively addressing the underlying aberrant expression, leading to ongoing muscle pathology and clinical weakness, with no specific treatment available for the disease.
Innovation Solution
Development of recombinant gene editing complexes comprising a gene editing protein and a guide RNA that specifically hybridizes to the D4Z4 macrosatellite repeat region on chromosome 4q35, inhibiting DUX4 gene expression, thereby reducing the production of the pathogenic DUX4-fl protein and its downstream targets.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies targeting DUX4 mRNA or protein are used, then some therapeutic effect is achieved, but the underlying aberrant expression is not effectively addressed, leading to ongoing muscle pathology
Solution Approach 1:
The CRISPR/Cas9 system performs preliminary action by targeting and disrupting the DUX4 gene at the DNA level before transcription occurs. The guide RNA directs Cas9 nuclease to specific sequences in the D4Z4 repeat region or DUX4 gene, creating double-strand breaks that prevent aberrant expression at its source, thereby addressing the root cause rather than treating downstream effects
Solution Approach 2:
The invention extracts the harmful DUX4 gene expression at its source by using CRISPR/Cas9 to specifically target and disrupt the aberrant transcription. The guide RNA sequence is designed to hybridize to the D4Z4 macrosatellite repeat region or DUX4 gene sequences, selectively removing the pathogenic expression while leaving normal genomic structure intact
2Ease of operation
If no specific therapy is available for FSHD, then current treatments can only address behavioral symptoms, but this results in inadequate treatment of the underlying disease
Solution Approach 1:
The invention changes the fundamental parameter of treatment approach by transitioning from symptomatic management to gene-level intervention. The CRISPR/Cas9 system enables specific molecular targeting of the DUX4 gene, fundamentally altering how FSHD can be treated by addressing the genetic root cause rather than merely managing clinical symptoms
3Reliability
If DUX4 expression is reduced by gene editing complexes, then disease symptomatology decreases, but this requires precise targeting of the D4Z4 macrosatellite repeat region
Solution Approach 1:
The guide RNA serves as an intermediary that mediates between the CRISPR/Cas9 system and the target DNA sequence. The guide RNA sequence is specifically designed to hybridize to the D4Z4 macrosatellite repeat region or DUX4 gene, providing precise directional guidance to the Cas9 nuclease and enabling accurate targeting without requiring direct protein-DNA recognition
Solution Approach 2:
The invention applies local quality by designing guide RNA sequences that are specific to particular regions of the D4Z4 array or DUX4 gene. Different guide RNA sequences can be tailored to target specific loci within the repetitive region, allowing precise local intervention while leaving other genomic regions unaffected
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The recombinant gene editing complexes effectively reduce DUX4 expression, decreasing disease symptomatology and potentially reversing muscle pathology by targeting the aberrant expression at its source, offering a novel approach to treating FSHD.
Implementation Method 1
a nucleic acid encoding a guide RNA (gRNA) that specifically hybridizes to a target nucleic acid sequence encoding a D4Z4 macrosatellite repeat region
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3A~3B
AI summary
The disclosure relates to methods and compositions for regulating expression of DUX4. Specifically, the disclosure provides a recombinant gene editing complex comprising: a recombinant gene editing protein; and, a nucleic acid encoding a guide RNA (gRNA) that specifically hybridizes to a target nucleic acid sequence encoding a D4Z4 macrosatellite repeat region, wherein binding of the complex to the target nucleic acid sequence results in inhibition of DUX4 gene expression. In some aspects, methods described by the disclosure are useful for treating a disease associated with aberrant DUX4 expression (e.g., facioscapulohumeral muscular dystrophy, FSHD).